Winston Pharmaceuticals

Winston Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the discovery and development of products for pain management. The company is headquartered in Vernon Hills, Illinois and currently employs 9 full-time employees. The company went IPO on 2006-02-23. The firm discovers, develops and commercializes therapeutics for managing and alleviating pain. The firm's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The firm is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The firm's other products are under development for the treatment of headache and neuropathic and rheumatological pain.